Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.58%570.69B | 3.06%518.81B | -3.53%2.1T | 2.77%484.92B | -4.72%559.25B | -9.02%556.31B | -1.39%503.4B | 14.65%2.18T | -7.16%471.85B | 17.47%586.97B |
Cost of revenue | -1.41%383.86B | -6.61%351.52B | -5.98%1.5T | -10.66%357.31B | -8.88%377.79B | -8.02%389.36B | 5.01%376.39B | 19.28%1.6T | 8.11%399.92B | 21.14%414.62B |
Gross profit | 11.91%186.83B | 31.71%167.29B | 3.16%603.02B | 77.40%127.61B | 5.28%181.46B | -11.28%166.95B | -16.48%127.01B | 3.67%584.52B | -48.01%71.93B | 9.50%172.35B |
Operating expense | 3.43%111.4B | 8.65%109.41B | 3.47%430.13B | 20.35%110.46B | 7.00%111.26B | -4.24%107.7B | -6.29%100.7B | 4.69%415.7B | -18.69%91.78B | 6.44%103.98B |
Selling and administrative expenses | 7.76%120.95B | 10.90%117.04B | 4.07%452.52B | 18.06%115.34B | 8.18%119.41B | -4.11%112.24B | -3.78%105.54B | 5.90%434.8B | -15.22%97.69B | 9.52%110.38B |
-General and administrative expense | 7.76%120.95B | 10.90%117.04B | 4.07%452.52B | 18.06%115.34B | 8.18%119.41B | -4.11%112.24B | -3.78%105.54B | 5.90%434.8B | -15.22%97.69B | 9.52%110.38B |
Other operating expenses | -110.66%-9.55B | -57.70%-7.63B | -17.20%-22.4B | 17.54%-4.88B | -27.33%-8.15B | 0.72%-4.53B | -116.90%-4.84B | -41.59%-19.11B | -151.57%-5.91B | -106.85%-6.4B |
Operating profit | 27.32%75.43B | 120.03%57.87B | 2.41%172.89B | 186.37%17.15B | 2.68%70.2B | -21.74%59.25B | -41.03%26.3B | 1.23%168.83B | -177.95%-19.85B | 14.51%68.37B |
Net non-operating interest income (expenses) | -24,780.77%-6.47B | 330.27%11.94B | 267.00%5.68B | 350.92%5.46B | 696.60%5.44B | -104.32%-26M | -465.54%-5.19B | -199.30%-3.4B | -3,463.93%-2.17B | -182.07%-911M |
Non-operating interest income | -11.37%6.98B | 137.47%15.48B | 106.67%35.9B | 20.13%7.03B | 193.14%14.48B | 104.71%7.87B | 115.25%6.52B | 54.05%17.37B | 219.04%5.85B | 53.40%4.94B |
Non-operating interest expense | 70.24%13.45B | -69.75%3.54B | 45.50%30.22B | -80.43%1.57B | 54.63%9.05B | 143.50%7.9B | 196.65%11.71B | 164.51%20.77B | 323.55%8.02B | 177.21%5.85B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -12,300.00%-1.22B | -141.35%-251M | -62.61%670M | -142.16%-481M | 61.69%1.25B | 103.28%10M | -155.91%-104M | -21.78%1.79B | 18.48%1.14B | 65.24%770M |
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 14.37%67.74B | 231.06%69.56B | 7.19%179.24B | 205.92%22.12B | 12.68%76.88B | -22.07%59.23B | -52.11%21.01B | -3.06%167.22B | -179.20%-20.88B | 11.34%68.23B |
Income tax | 8.68%20.74B | 58.20%9.1B | 0.36%53.11B | 626.46%16.88B | -37.71%11.38B | -5.55%19.09B | -52.49%5.75B | 30.10%52.92B | -80.98%2.32B | 45.56%18.27B |
Net income | 17.07%47B | 296.25%60.46B | 10.35%126.14B | 122.56%5.24B | 31.12%65.5B | -28.05%40.14B | -51.96%15.26B | -13.29%114.3B | -264.04%-23.21B | 2.52%49.95B |
Net income continuous operations | 17.07%47B | 296.25%60.46B | 10.35%126.14B | 122.56%5.24B | 31.12%65.5B | -28.05%40.14B | -51.96%15.26B | -13.29%114.3B | -264.04%-23.21B | 2.52%49.95B |
Noncontrolling interests | 34.41%914M | 56.29%833M | 1,170.18%1.45B | 107.71%40M | 572.41%195M | 164.59%680M | 53.60%533M | -77.95%114M | -567.57%-519M | -91.19%29M |
Net income attributable to the company | 16.78%46.08B | 304.94%59.63B | 9.20%124.69B | 122.90%5.2B | 30.80%65.3B | -28.94%39.46B | -53.12%14.73B | -13.03%114.19B | -261.64%-22.69B | 3.16%49.92B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 16.78%46.08B | 304.94%59.63B | 9.20%124.69B | 122.90%5.2B | 30.80%65.3B | -28.94%39.46B | -53.12%14.73B | -13.03%114.19B | -261.64%-22.69B | 3.16%49.92B |
Gross dividend payment | ||||||||||
Basic earnings per share | -46.44%11.144 | 304.82%31.43 | 9.13%65.74 | 122.87%2.738 | 30.77%34.428 | -28.99%20.808 | -53.16%7.764 | -13.06%60.238 | -261.68%-11.974 | 3.09%26.328 |
Diluted earnings per share | -46.44%11.128 | 304.90%31.388 | 9.16%65.638 | 122.83%2.734 | 30.79%34.376 | -28.96%20.776 | -53.11%7.752 | -13.02%60.128 | -261.99%-11.974 | 3.15%26.284 |
Dividend per share | 20.69%14 | 0 | 9.43%23.2 | 9.43%11.6 | 0 | 9.43%11.6 | 0 | 38.26%21.2 | 17.78%10.6 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |